<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01997788</url>
  </required_header>
  <id_info>
    <org_study_id>ITMPKidney</org_study_id>
    <nct_id>NCT01997788</nct_id>
  </id_info>
  <brief_title>The Intrathecal Morphine for Nephrectomy</brief_title>
  <acronym>EMPON</acronym>
  <official_title>The Efficacy of Intrathecal Morphine in Patients Undergoing Open Nephrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and the safety of the intrathecal morphine injection in the open
      nephrectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The open nephrectomy is the treatment of choice for live donor kidney transplantation and
      renal cell carcinoma. The incision for the nephrectomy causes severe postoperative pain. A
      single dose of intrathecal morphine(ITM) has been used for the postoperative pain of
      prostatectomy, transurethral resection of the prostate and hepatectomy. The effect of ITM for
      open nephrectomy has not been studied. Therefore, this prospective, randomized study will
      evaluate the efficacy and safety of a single 50 mcg dose of ITM added to intravenous patient
      controlled analgesia(IV-PCA), comparing to IV-PCA alone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The evaluation of pain at 24 hours after surgery</measure>
    <time_frame>at postoperatively 24 hours</time_frame>
    <description>The doctor blinded to the investigation will visit patients. The pain will be assessed at rest and at coughing using visual analogue scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The consumption of analgesics</measure>
    <time_frame>at postoperatively 24 hours</time_frame>
    <description>The total amount of opioids (IV morphine) used for 24 hours after surgery will be recorded and compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The consumption of intraoperative opioids</measure>
    <time_frame>From the induction of anesthesia till the emergence of anesthesia, an expected average of 4 hours</time_frame>
    <description>The total amount of intraoperative opioids (IV remifentanil) will be recorded and compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The side effects of opioids after surgery</measure>
    <time_frame>During 72 hours after the end of surgery</time_frame>
    <description>Any side effects of opioids including nausea, vomiting, dizziness, sedation, headache, pruritus and respiratory depression will be recorded.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>The ITM group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The postoperative pain management includes both the intrathecal morphine injection and the intravenous patient-controlled analgesia. Demerol on demand will be injected intravenously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The IV-PCA group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The postoperative pain management includes only the intravenous patient-controlled analgesia. Demerol on demand will be injected intravenously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>The intrathecal morphine injection</intervention_name>
    <description>A single injection of morphine intrathecally</description>
    <arm_group_label>The ITM group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>The intravenous patient-controlled analgesia</intervention_name>
    <description>The intravenous injection of morphine using the patient-controlled analgesia machine</description>
    <arm_group_label>The ITM group</arm_group_label>
    <arm_group_label>The IV-PCA group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Demerol on demand</intervention_name>
    <description>Demerol 25 mg intravenously when pain scores more than 5.</description>
    <arm_group_label>The ITM group</arm_group_label>
    <arm_group_label>The IV-PCA group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for the open nephrectomy

        Exclusion Criteria:

          -  Patients with renal insufficiency

          -  Patients with coagulopathy

          -  History of any neurologic disorder

          -  History of recent infection in 2 weeks

          -  History of drug abuse

          -  Patients who cannot understand the usage of th intravenous patient-controlled
             analgesia

          -  Patients using opioids due to the chronic pain
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deok-Man Hong, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Seoul National University of Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University of Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2013</study_first_submitted>
  <study_first_submitted_qc>November 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2013</study_first_posted>
  <last_update_submitted>July 1, 2015</last_update_submitted>
  <last_update_submitted_qc>July 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Deok Man Hong</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Injection, Spinal</keyword>
  <keyword>Morphine</keyword>
  <keyword>Analgesia</keyword>
  <keyword>Patient-Controlled</keyword>
  <keyword>Pain</keyword>
  <keyword>Postoperative</keyword>
  <keyword>Combined Modality Therapy</keyword>
  <keyword>Nephrectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Meperidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

